Physician profile
Rachael Daniel
NPI 1386260537
$1,061.11
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.18 · 2023: $491 · 2024: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.78 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $641.19 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.62 | 2023-2024 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $50.18 | 2021 | |
| Neurocrine Biosciences, INC. | $43.62 | 2023-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $34.37 | 2023-2024 | Nuedexta, Rexulti |
| Corium, LLC | $28.60 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $18.13 | 2024 | Uzedy |
| Bausch Health US, LLC | $17.54 | 2023 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $17.09 | 2024 | Spravato |
| Noven Therapeutics, LLC | $14.77 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.